The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients With Peripheral Arterial Disease (SPAD Study)

Summary

The purpose of this study is to investigate the Safety and Efficacy of Cilostazol in slowing down the progression of peripheral arterial disease (PAD) in ischemic stroke patients with PAD in Taiwan.

Conditions

• Ischemic Stroke

Interventions

DRUG

Cilostazol

100 mg, bid p.o.

OTHER

placebo

1 tablet, bid

Sponsors & Collaborators

• National Taiwan University Hospital

  collaborator OTHER

• Shin Kong Wu Ho-Su Memorial Hospital

  collaborator OTHER

• Tri-Service General Hospital

  collaborator OTHER

• Far Eastern Memorial Hospital

  collaborator OTHER

• Changhua Christian Hospital

  collaborator OTHER

• Chi Mei Medical Hospital

  collaborator OTHER

• National Cheng-Kung University Hospital

  collaborator OTHER

• Kaohsiung Medical University Chung-Ho Memorial Hospital

  collaborator OTHER

• E-DA Hospital

  collaborator OTHER

• Mackay Memorial Hospital

  collaborator OTHER

• Cathay General Hospital

  collaborator OTHER

• En Chu Kong Hospital

  collaborator OTHER

• Kuang Tien General Hospital

  collaborator OTHER

• Chung Shan Medical University

  collaborator OTHER

• Taipei Veterans General Hospital, Taiwan

  collaborator OTHER_GOV

• China Medical University Hospital

  lead OTHER

Principal Investigators

• Chung Y. Hsu, MD. Ph.D. · China Medical University Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

50 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2010-09-30

Primary Completion

2013-07-31

Completion

2013-07-31